489 related articles for article (PubMed ID: 33682378)
1. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.
Coates LC; Pillai SG; Tahir H; Valter I; Chandran V; Kameda H; Okada M; Kerr L; Alves D; Park SY; Adams DH; Gallo G; Hufford MM; Hojnik M; Mease PJ; Kavanaugh A;
Arthritis Rheumatol; 2021 Sep; 73(9):1663-1672. PubMed ID: 33682378
[TBL] [Abstract][Full Text] [Related]
2. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
3. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
[TBL] [Abstract][Full Text] [Related]
5. Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.
Mease P; Roussou E; Burmester GR; Goupille P; Gottlieb A; Moriarty SR; Benichou O; Adams DH; Xu W; Nash P
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):367-378. PubMed ID: 30156760
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
Genovese MC; Combe B; Kremer JM; Tsai TF; Behrens F; Adams DH; Lee C; Kerr L; Nash P
Rheumatology (Oxford); 2018 Nov; 57(11):2001-2011. PubMed ID: 30053162
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
8. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
[TBL] [Abstract][Full Text] [Related]
11. Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
Tillett W; Lin CY; Trevelin Sprabery A; Birt JA; Kavanaugh A
Clin Exp Rheumatol; 2020; 38(6):1227-1230. PubMed ID: 32452352
[TBL] [Abstract][Full Text] [Related]
12. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.
Kavanaugh A; Marzo-Ortega H; Vender R; Wei CC; Birt J; Adams DH; Benichou O; Lin CY; Nash P
Clin Exp Rheumatol; 2019; 37(4):566-574. PubMed ID: 30557128
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Coates LC; Mease P; Kronbergs A; Helt C; Sandoval D; Park SY; Combe B; Nash P; Deodhar A
Clin Rheumatol; 2022 Oct; 41(10):3035-3047. PubMed ID: 35674861
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
[TBL] [Abstract][Full Text] [Related]
16. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
Genovese MC; Braun DK; Erickson JS; Berclaz PY; Banerjee S; Heffernan MP; Carlier H
J Rheumatol; 2016 Feb; 43(2):289-97. PubMed ID: 26669919
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
19. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
